For those of you in doubt about Abbott, I know they are very stealth about Recaf, but we are mentioned when they talk about cancer markers. Here is what I found in one their oncology memos......
Future Tumour Markers
To supplement these established cancer assays,
Abbott researchers are working on developing
immunoassays for a number of additional, cuttingedge
tumour markers.
Table 1
Abbott Tumour Markers.
Another marker under development is receptor for alpha-fetoprotein-fatty
acid complex (RECAF). Existing data from
prototype assays have demonstrated both high
sensitivity and high specificity for the early detection
of several major types of cancer including breast,
colorectal, prostate, ovarian and lung.
............................................................................................................................
Abbott is still on board, things are obviously progressing.
News 
Market Data 
Discover 
AI
